Hofer & Associates
ABBV icon

Hofer & Associates’s AbbVie ABBV Stock Holding History

Hofer & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-3,330
Closed -$838K – 79
2026
Q2 		$838K Buy
3,330
+105
+3% +$22.6K 0.41% 35
2026
Q1 		$701K Buy
3,225
+65
+2% +$14.4K 0.38% 34
2025
Q4 		$722K Buy
3,160
+25
+0.8% +$5.7K 0.38% 34
2025
Q3 		$726K Buy
+3,135
New +$638K 0.42% 33

Other funds holding ABBV

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return
Cardano Risk Management
Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return
Sepio Capital
Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return
Hamlin Capital Management
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Hofer & Associates's ABBV Position: Q3 2026 in Review

Hofer & Associates sold out of AbbVie (ABBV) in Q3 2026, closing a stake of 3,330 shares — an estimated $838K sold.

Hofer & Associates first reported a position in ABBV in Q3 2025 and held it in 4 quarters. The position peaked at $838K in Q2 2026. 1,657 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Hofer & Associates reported no remaining AbbVie position as of Q3 2026 after selling out during the quarter.
  • Hofer & Associates sold 3,330 AbbVie shares in Q3 2026, an estimated $838K.
  • Hofer & Associates first reported a position in AbbVie in Q3 2025 and held it in 4 quarters.
  • Hofer & Associates's AbbVie position peaked at $838K in Q2 2026.
  • 1,657 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Hofer & Associates's 13F filing for Q3 2026, filed 13 Oct 2026.